Daily Stock Analysis, GILD, Gilead Sciences Inc, priceseries

Gilead Sciences Inc. Daily Stock Analysis
Stock Information
Open
67.74
Close
66.98
High
67.74
Low
66.58
Previous Close
67.99
Daily Price Gain
-1.01
YTD High
68.16
YTD High Date
Jan 19, 2021
YTD Low
57.93
YTD Low Date
Jan 4, 2021
YTD Price Change
6.87
YTD Gain
11.43%
52 Week High
83.36
52 Week High Date
Mar 19, 2020
52 Week Low
56.40
52 Week Low Date
Oct 29, 2020
52 Week Price Change
6.11
52 Week Gain
10.03%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 20. 2017
58.00
Jul 6. 2017
61.29
11 Trading Days
5.66%
Link
LONG
Jul 17. 2017
62.92
Aug 3. 2017
66.11
13 Trading Days
5.07%
Link
LONG
Aug 23. 2017
65.21
Sep 14. 2017
72.71
15 Trading Days
11.50%
Link
LONG
Jan 9. 2018
69.99
Feb 1. 2018
74.22
16 Trading Days
6.04%
Link
LONG
Jul 2. 2018
64.85
Jul 27. 2018
69.83
18 Trading Days
7.68%
Link
Company Information
Stock Symbol
GILD
Exchange
NasdaqGS
Company URL
http://www.gilead.com
Company Phone
6505743000
CEO
John F. Milligan
Headquarters
Business Address
333 LAKESIDE DR, FOSTER CITY, CA 94404
Sector
Equity
Industry Category
Industry Group
CIK
About

Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need. It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology & oncology, and cardiovascular & inflammation as well as respiratory diseases. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera, Atripla, Truvada, Viread, Emtriva, Tybost, Vitekta, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, Hepsera, Zydelig, Letairis, Ranexa, Lexiscan, Cayston, Tamiflu, AmBisome and Macugen. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Description

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.